Combatting the rising costs of cancer drugs; interventions from a university hospital’s perspective

Aniek Dane*, Roelof van Leeuwen, Maaike Hoedemakers, Hugo van der Kuy, Stefan Sleijfer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Downloads (Pure)

Abstract

Rapid increase in cost continues to have negative impact on patients’ accessibility to life-changing anticancer medications. Moreover, the rising cost does not equate to similar increase in medication effectiveness. We recognise our responsibility as a university hospital to tackle this imbalance and strive to provide high quality, sustainable, affordable and accessible care. An active approach in cost containment of expensive and innovative cancer drugs was adopted in our organisation to safeguard accessibility and improve quality of life for patients. In this article, we described four inverventions: 1) identify right patient and minimise overtreatment, 2) in-house medicine production for selected indications, 3) minimise medicine spillages and 4) effective procurement strategies. We call on other hospitals to take action and, favourably, to collaborate on a European level. Together, we will safeguard the current and future care of our patients.

Original languageEnglish
Article number1264951
Number of pages7
JournalFrontiers in Pharmacology
Volume14
DOIs
Publication statusPublished - 28 Aug 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023 Dane, van Leeuwen, Hoedemakers, van der Kuy and Sleijfer.

Fingerprint

Dive into the research topics of 'Combatting the rising costs of cancer drugs; interventions from a university hospital’s perspective'. Together they form a unique fingerprint.

Cite this